The detailed planning work that has taken place in recent months has been worthwhile. IHF GmbH developed the study design together with Professor Dr Julinda Mehilli, Director and Initiator of REBOOT PARADOX. The ethics committee was happy with the study and approved it without conditions.
The REBOOT PARADOX study investigates treatment approaches for patients with paradoxical aortic valve stenosis. It compares quality of life and mortality rates of patient groups with replacement aortic valves who also received drug treatment and patient groups receiving only drug treatment.
